¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"cell injury"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
  • high-threshold cell
    °í¹®Åΰª¼¼Æ÷
  • horizontal cell
    ¼öÆò¼¼Æ÷
  • horny cell
    °¢Áú¼¼Æ÷
  • human diploid cell vaccine
    »ç¶÷µÎ¹è¼ö¼¼Æ÷¹é½Å
  • human T-cell lymphoma/leukemic virus
    »ç¶÷T¼¼Æ÷¸²ÇÁÁ¾/¹éÇ÷º´¹ÙÀÌ·¯½º
  • human T-cell lymphotropic virus
    »ç¶÷T¼¼Æ÷¸²ÇÁģȭ¹ÙÀÌ·¯½º
  • Hurthle cell adenoma
    ÈÖ¸£Æ²·¹¼¼Æ÷»ùÁ¾
  • hybrid cell
    ÀâÁ¾¼¼Æ÷
  • islet cell
    ¼¶¼¼Æ÷
  • islet cell adenoma
    ¼¶¼¼Æ÷»ùÁ¾
  • islet cell carcinoma
    ¼¶¼¼Æ÷¾ÏÁ¾
  • immunologically competent cell
    ¸é¿ª¼¼Æ÷
  • indeterminate cell
    ºÎÁ¤Çü¼¼Æ÷
  • indifferent cell
    ¹«°ü¼¼Æ÷
  • inducer cell
    À¯µµ¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
  • mastoid air cell
    ²ÀÁö¹úÁý
  • matrix cell
    ±âÁú¼¼Æ÷, ÅйÙÅÁÁú¼¼Æ÷
  • memory cell
    ¸é¿ª±â¾ï¼¼Æ÷
  • Merkel cell-neurite complex
    Ã˰¢¼¼Æ÷½Å°æµ¹±âº¹ÇÕü
  • mesangial cell
    Ç÷°ü»çÀ̼¼Æ÷
  • mesenchymal cell
    Áß°£¿±¼¼Æ÷
  • mesothelial cell
    ÁßÇǼ¼Æ÷
  • microglial cell
    ¹Ì¼¼¾Æ±³¼¼Æ÷
  • mitotic cell
    ºÐ¿­±â¼¼Æ÷
  • mitral cell
    ½Â¸ð¼¼Æ÷
  • mononuclear cell
    ´ÜÇÙ¼¼Æ÷
  • mossy cell
    À̳¢¼¼Æ÷
  • mother cell
    ¸ð¼¼Æ÷, ¾î¹Ì¼¼Æ÷
  • motor cell
    ¿îµ¿½Å°æ¼¼Æ÷
  • mucous cell
    Á¡¾×¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
  • hairy cell
    ¸ð¹ß»ó¼¼Æ÷.
  • hairy cell
    ¸ð¹ß»ó¼¼Æ÷
  • hairy cell leukemia
    ¸ð¹ß»ó¼¼Æ÷¹éÇ÷º´
  • hairy cell leukemia
    ¸ð¹ß»ó¼¼Æ÷¹éÇ÷º´, Åм¼Æ÷¹éÇ÷º´
  • hairy cell leukemia
    Åм¼Æ÷ ¹éÇ÷º´
  • hairy cell leukemia
    ¸ð¹ß»ó¼¼Æ÷ ¹éÇ÷º´
  • hairy-cell leukemia
    ¸ð¹ß»ó¼¼Æ÷¹éÇ÷º´
  • heart failure cell
    ½ÉºÎÀü¼¼Æ÷(¡­á¬øà)
  • helmet cell
    Åõ±¸¼¼Æ÷
  • helper T cell
    Á¶·ÂT¼¼Æ÷, º¸Á¶T¼¼Æ÷
  • helper T cell
    º¸Á¶ T¼¼Æ÷
  • helper T cell
    º¸Á¶ T ¼¼Æ÷
  • helper cell
    º¸Á¶¼¼Æ÷
  • helper cell
    Á¶·Â¼¼Æ÷, º¸Á¶¼¼Æ÷
  • helper cell activity
    Á¶·Â¼¼Æ÷´É, º¸Á¶¼¼Æ÷´É
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
  • cell associated antigen
    ¼¼Æ÷¿¬°üÇ׿ø
  • cell bank
    ¼¼Æ÷ÀºÇà
  • cell body
    ¼¼Æ÷ü(á¬øàô÷)
  • cell color ratio
    (Àû)Ç÷±¸»ö¼Òºñ.
  • cell cooperation, T-B
    T¼¼Æ÷-B¼¼Æ÷Çùµ¿
  • cell count
    ¼¼Æ÷¼ö
  • cell culture
    ¼¼Æ÷¹è¾ç(á¬øàÛÆå×).
  • cell culture
    ¼¼Æ÷¹è¾ç
  • cell culture
    ¼¼Æ÷¹è¾ç
  • cell culture
    Á¶Á÷ ¼¼Æ÷¹è¾ç(á¬øàÛÆå×)
  • cell culture, slide
    ½½¶óÀ̵弼Æ÷¹è¾ç
  • cell cycle
    ¼¼Æ÷ÁÖ±â(¡­ñ²Ñ¢)
  • cell cycle
    ¼¼Æ÷ÁÖ±â
  • cell cycle
    ¼¼Æ÷ÁÖ±â
  • cell cycle
    ¼¼Æ÷ÁÖ±â
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 17
ARFC active rosette-forming T-cell; autologous rosette-forming cell
ATL Achilles tendon lengthening; acute T-cell leukemia; adult T-cell leukemia; anterior tricuspid leafle...
BCM B-cell maturation; birth control medication; blood-clotting mechanism effects; body cell mass; body ...
BMC blood mononuclear cell; bone marrow cell; bone mineral content
CAM calf aortic microsome; cell adhesion molecule; cell-associating molecule; chorioallantoic membrane; ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 17
B CLL B cell chronic lymphocytic leukemia
BCDF B cell differentiation factor
BCGF II B cell growth factor II
BCL1 B cell leukemia
BLPD B cell lympho-proliferative disorders
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • mother cell
    ¸ð¼¼Æ÷
  • motility of cell
    ¿îµ¿¼º ¼¼Æ÷
  • motor cell
    ¿îµ¿ ½Å°æ ¼¼Æ÷
  • mucous cell
    Á¡¾× ¼¼Æ÷
  • mucous neck cell
    Á¡¾×°æ ¼¼Æ÷
  • mucus-secreting cell
    Á¡¾× ºÐºñ ¼¼Æ÷
  • multilocular fat cell
    ¹µÄ­ Áö¹æ ¼¼Æ÷
  • multinucleated cell
    ´ÙÇÙ ¼¼Æ÷
  • multinucleated giant cell
    ´ÙÇÙ °Å´ë ¼¼Æ÷, °Å´ë ´ÙÇÙ ¼¼Æ÷, ´ÙÇÙ °Å¼¼Æ÷
  • multipolar nerve cell
    ¹µ ±Ø ½Å°æ ¼¼Æ÷, ´Ù±Ø ½Å°æ ¼¼Æ÷
  • muscle cell
    ±Ù ¼¼Æ÷
    ´Éµ¿ÀûÀ¸·Î ¼öÃ༺À» º¸ÀÌ´Â µ¿¹°Ã¼³»ÀÇ ¼¼Æ÷. ±ÙÀ° ¼¼Æ÷¶ó°íµµ ÇÑ´Ù. ±Ù Á¶Á÷À» ±¸¼ºÇÏ´Â °æ¿ì °¢°¢ÀÇ ±Ù ¼¼Æ÷´Â ÀϹÝÀûÀ¸·Î ¹æÃß»ó ¶Ç´Â ¼¶À¯»óÀ» ¶í´Ù. ÇØ¸éµ¿¹°Àº ±ÙÁ¶Á÷ÀÌ ¾øÀ¸³ª, ±Ô°¢ ÇØ¸é·ù¿¡¼­´Â üǥÀÇ ÆíÆò»óÇÇ ¼¼Æ÷°¡ ¾ó¸¶°£ ¼öÃ༺À» °¡Áö¸ç, üǥ ƯÈ÷ À¯Ãâ°ø ÁÖº¯¿¡ ¹Ì¿À»çÀÌÆ®¶ó°í ÇÏ´Â ±ä ¹æÃßÇüÀÇ ¼öÃ༺ ¼¼Æ÷°¡ Á¸ÀçÇÑ´Ù. ¶Ç ¼®È¸ ÇØ¸é·ùÀÇ ¼Ò°ø ¼¼Æ÷¿¡µµ ¼öÃ༺ÀÌ ÀÎÁ¤µÈ´Ù. À̵éÀº ¾î¶² Á¾·ùÀÇ ¿ø»ýµ¿¹° ¸ö Àüü¿¡ ³ªÅ¸³ª´Â ¼öÃ༺°ú ´õºÒ¾î ±Ù ¼¼Æ÷°¡ ³ªÅ¸³ª´Â ½ÃÀÛ ÇüÅ·Π°£ÁֵȴÙ. °­À嵿¹°ÀÇ Æú¸³Çü¿¡¼­´Â ¿Ü¹è¿± ¼¼Æ÷ Ãþ ¼Ó¿¡ ÀÖ´Â »óÇÇ ±Ù ¼¼Æ÷¿¡ ÁøÁ¤ÇÑ ±Ù¿ø¼¶À¯°¡ ÀÖ´Ù. À̰ÍÀº °¡Àå ÈçÈ÷ ÀÖ´Â ¿øÁÖ»óÇÇ ¼¼Æ÷, ÁïÁöÁö ¼¼Æ÷ÀÇ ±âÀúºÎ°¡ ¹æÃßÇüÀ¸·Î ´Ã¾î³ª¼­ ±× ºÎºÐ¿¡ ÇÑÇØ¼­ ±Ù¿ø¼¶À¯°¡ Á¸ÀçÇÏ´Â °ÍÀ¸·Î, üǥÀÇ »óÇÇ ¼¼Æ÷¿¡¼­ ±Ù¼¼Æ÷·Î ºÐÈ­ÇÏ´Â µµÁßÀÇ °ÍÀÌ´Ù. ÇØÆÄ¸® Çü¿¡¼­´Â ¹æÃßÇü ±Ù ¼¼Æ÷°¡ ¿Ï¼ºµÈ´Ù. ÆíÇüµ¿¹° À̻󿡼­´Â ÇDZÙÃþ, ±â°ü±Ù µî ºÐÈ­°¡ ÇöÀúÇÏ´Ù.
  • muscle-cell
    ±Ù ¼¼Æ÷
  • mycosis cell
    ¸¶ÀÌÄڽýº ¼¼Æ÷, Áø±Õ ¼¼Æ÷
    ¸¹Àº ºñÁ¤Çü ¸²ÇÁ°è ¼¼Æ÷ÀÇ Çϳª·Î¼­ °ú¿°»ö¼ºÀÇ ½ÉÇÑ È¸¼±»ó ÇÙÀ» °¡Áö°í ÀÖÀ¸¸ç ¿øÁ¶/À¯µµ ¼¼Æ÷ Ç¥ÇöÇüÀÇ T ¼¼Æ÷¿¡¼­ À¯·¡ÇÑ °ÍÀ¸·Î º¸ÀδÙ. ¿ë»ó Áø±ÕÁõ¿¡¼­ »óÇdzª ÆÄ¿ìÆ®¸®¾î
  • myoid cell
    ±ÙÀ°¾ç ¼¼Æ÷
  • natural kil1er cell
    ÀÚ¿¬ »ì¼¼Æ÷
    ¼±Ãµ¼º ¸é¿ªÀÇ Áß¿ä ÀÎÀÚ. ¼¼Æ÷ ³»¿¡ azuro
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
CD4 cell T helper cells which are targets for HIV infection.
(09 Oct 1997)
CD4 cell count The most commonly used surrogate marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. The normal range for CD4 cell counts is 500 to 1500 per cubic millimetre of blood. CD4 count should be rechecked at least every six to twelve months if CD4s are greater than 500/mm3. If the count is lower, testing every three months is advised.
(09 Oct 1997)
virus-transformed cell A cell that has been genetically changed to a tumour cell, the change being subsequently tramsmitted to all descendent cell's; cell's transformed by oncornaviruses continue to produce virus in high concentration without being killed; DNA tumour virus-transformed cell's develop (along with other changes) tumour-associated antigens and rarely produce virus.
(05 Mar 2000)
CD8 cell <immunology> One type of T-lymphocyte which bears the CD8 molecular marker on its surface. Some CD8 cells recognise and kill cancerous cells and those infected by intracellular pathogens (some bacteria, viruses and mycoplasma). These cells are called cytotoxic T-lymphocytes (see).
(09 Oct 1997)
glomerulosa cell A cell of the zona glomerulosa of the adrenal cortex that is the source of aldosterone; the cell's are arranged in spherical or oval groups.
(05 Mar 2000)
cell <cell biology> An autonomous self replicating unit (in principle) that may constitute an organism (in the case of unicellular organisms) or be a sub unit of multicellular organisms in which individual cells may be more or less specialised differentiated) for particular functions.
The individual units from which tissues of the body are formed. All living organisms are composed of one or more cells.
(26 Mar 1998)
cell adhesion See: adhesins, cadherins, cell adhesion molecules (CAMs), contact sites A, DLVO theory, integrins, sorting out, uvomorulin and various specialised junctions (adherens junctions, desmosomes, focal adhesions, gap junction and zonula occludens).
(18 Nov 1997)
cell adhesion kinase <enzyme> From hela cells; involved in cell-cell interactions; genbank l20817
Registry number: EC 2.7.1.-
Synonym: cak protein
(26 Jun 1999)
cell adhesion molecule <molecular biology> Although this could mean any molecule involved in cellular adhesive phenomena, it has acquired a more restricted sense, namely a molecule on the surface of animal tissue cells, antibodies (or Fab fragments) against that specifically inhibit some form of intercellular adhesion.
Examples are Liver Cell Adhesion Molecule and Neural Cell Adhesion Molecule, both named from tissues in which first detected, although their occurrence is not in fact restricted to these.
Acronym: CAM
(26 Nov 1998)
cell adhesion molecules Surface ligands, usually glycoproteins, that mediate cell-to-cell adhesion. Their functions include the assembly and interconnection of various vertebrate systems, as well as maintenance of tissue integration, wound healing, morphogenic movements, cellular migrations, and metastasis.
(12 Dec 1998)
cell adhesion molecules, neuronal Surface ligands that mediate cell-to-cell adhesion and function in the assembly and interconnection of the vertebrate nervous system. These molecules promote cell adhesion via a homophilic mechanism. These are not to be confused with ncam (neural cell adhesion molecule), now known to be expressed in a variety of tissues and cell types in addition to nervous tissue.
(12 Dec 1998)
cell adhesion molecules, neuron-glia Cell adhesion molecules that mediate neuron-neuron adhesion and neuron-astrocyte adhesion. They are expressed on neurons and schwann cells, but not astrocytes and are involved in neuronal migration, neurite fasciculation, and outgrowth. Ng-cam is immunologically and structurally distinct from ncam (neural cell adhesion molecules).
(12 Dec 1998)
cell aggregation The phenomenon by which dissociated cells intermixed in vitro tend to group themselves with cells of their own type.
(12 Dec 1998)
cell aging The decrease in the cell's ability to proliferate with the passing of time. Each cell is programmed for a certain number of cell divisions and at the end of that time proliferation halts. The cell enters a quiescent state after which it experiences cell death via the process of apoptosis.
(12 Dec 1998)
cell behaviour <cell biology> General term for activities of whole cells such as movement, adhesion and proliferation, by analogy with animal behaviour.
(18 Nov 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 17
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 17
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 17
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 17
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 17
ÅëÇÕ°Ë»ö ¿Ï·á